Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

Novo Nordisk A/S (NYSE:NVO) is one of the Best Non-US Stocks to Buy According to Hedge Funds. On December 12, Novo Nordisk ...

Novo Nordisk trades 32% below fair value with a 3.6% yield, semaglutide at 74% of sales, EPS rebound post '26, and pipeline ...

Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection ...

The imminent Indian patent expiry of Novo Nordisk’s global blockbuster anti-diabetic and weight loss treatment drug – the GLP ...

Danish pharma giant Novo Nordisk's recent launch of Ozempic in India alongside a 37% price cut on Wegovy points out at more ...

The pills are expected to cost much less then shots of blockbuster drugs like Zepbound and Wegovy. Mr. Funk was the managing ...

In November 2025, US President Donald Trump announced transformative actions to lower prescription drug costs and secure the ...

President Donald Trump announced nine of the largest drugmakers in the U.S. and Europe agreed to voluntarily sell their ...

Healthcare stocks haven't gotten a lot of love from investors in recent years. While the market has been strong and the S&P 500 has rallied by 84% in the past five years, the Health Care Select Sector ...

People who switched to the experimental daily GLP-1 pill orforglipron were able to maintain their weight loss after stopping ...